The blockade of immune checkpoints in cancer immunotherapy - Wikidata - wikimedia - TriplyDB

The blockade of immune checkpoints in cancer immunotherapy

The blockade of immune checkpoints in cancer immunotherapy

http://www.wikidata.org/entity/Q27860852

about

Oncolytic viruses as therapeutic cancer vaccines Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy Multi-organ Mapping of Cancer Risk Immunobiology of hepatocarcinogenesis: Ways to go or almost there?Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatment PD-L1 expression in human cancers and its association with clinical outcomes Immunobiology and immunotherapy in genitourinary malignancies Harnessing the immune system to improve cancer therapy A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints Non-small cell lung cancer: current treatment and future advances CD8 T Cell-Independent Antitumor Response and Its Potential for Treatment of Malignant Gliomas Immune Checkpoint Inhibitors and Prostate Cancer: A New Frontier?New targeted treatments for non-small-cell lung cancer - role of nivolumab Oncolytic Viruses: Therapeutics With an Identity Crisis Producer T cells: Using genetically engineered T cells as vehicles to generate and deliver therapeutics to tumors A Perspective of Immunotherapy for Prostate Cancer Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer?The role of pembrolizumab in the treatment of advanced non-small cell lung cancer Immunotherapy for human papillomavirus-associated disease and cervical cancer: review of clinical and translational research Immune checkpoint blockade therapy for bladder cancer treatment Effector, Memory, and Dysfunctional CD8(+) T Cell Fates in the Antitumor Immune Response Turning-Off Signaling by Siglecs, Selectins, and Galectins: Chemical Inhibition of Glycan-Dependent Interactions in Cancer Engineered Swine Models of Cancer Inhibiting Immune Checkpoints for the Treatment of Bladder Cancer Dendritic-Tumor Fusion Cell-Based Cancer Vaccines Checkpoint Inhibitors and Their Application in Breast Cancer Current and emerging therapies in unresectable and recurrent gastric cancer The Immunogenicity of Colorectal Cancer in Relation to Tumor Development and Treatment Profile of nivolumab in the treatment of metastatic squamous non-small-cell lung cancer Potential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosis NK Cells, Tumor Cell Transition, and Tumor Progression in Solid Malignancies: New Hints for NK-Based Immunotherapy?Survivin: a unique target for tumor therapy The emerging role of immunotherapy in head and neck squamous cell carcinoma (HNSCC): anti-tumor immunity and clinical applications Have lessons from past failures brought us closer to the success of immunotherapy in metastatic pancreatic cancer?Targeted immunotherapy for pediatric solid tumors Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting Case Characterization, Clinical Features and Risk Factors in Drug-Induced Liver Injury Overcoming Hypoxia-Mediated Tumor Progression: Combinatorial Approaches Targeting pH Regulation, Angiogenesis and Immune Dysfunction Advances in inducing adaptive immunity using cell-based cancer vaccines: Clinical applications in pancreatic cancer Marrow-Infiltrating Lymphocytes - Role in Biology and Cancer Therapy

P2860

Q21245758-BAC54DF9-F137-47F2-823E-49CF86546E52 Q24187274-9AF9936C-2D54-4B0C-87E3-6C064C2BE4FD Q26701396-07CBBE9C-C470-48B6-B094-E7AA0D4D769F Q26738293-E57EFD64-8F66-4F9A-B12D-D8CED3B430A2 Q26738359-69BFB9A1-D6DA-4462-B5FB-3EFCD7EB9A2F Q26738361-9930FA0D-E7B2-4630-BFE0-6E12A090070C Q26738668-F2ECD793-D5B1-4AB4-842C-0BF67C013204 Q26738698-F7FE055C-34AB-404B-8B42-6CB6B46B90BE Q26738729-573A4499-01D2-47A3-9319-987C9A95400B Q26740333-56515B7A-16E2-4341-BC40-88677EE26B76 Q26740520-4818D1DA-FC9F-4610-A022-81ADD5A9BFDE Q26740601-29B88DB4-E7B1-4AE8-97A5-D50EE835DE2E Q26740988-21298D42-8F6C-4A33-88D7-62D6FF25EDF3 Q26741020-53DC6281-15E9-4EFD-AF4F-45BF30DC2E0D Q26741260-D3C6CE9F-F51F-42AF-9A82-9E1A85E2E44C Q26741277-9E449671-A4BF-418E-8483-31C4B3A93F80 Q26742047-D0F87B61-366D-43A6-A16C-AAC027240AFF Q26744076-BEAB7B8B-FFB7-43DF-AE10-C2060270BD5A Q26744094-A56A0690-AACE-4F28-BFD5-B51DD03A8658 Q26744139-0DD6ABEC-EEBA-4BC2-AC6D-1D8C7E646602 Q26744527-8A4C8D90-5F89-4264-8285-A6A4AE51353C Q26744538-DE3407FC-A2D6-490E-92E7-520D65D46ED5 Q26744575-8E6E64C3-CC0B-451F-AEFA-A325834AB4E6 Q26744758-C98982B2-F5D1-4FEE-ADA6-494983C8FE04 Q26744827-738A3855-0983-4682-9BDA-FA63669A378B Q26745442-BFE3BAE4-2CE0-45D9-95A7-B6709AD0C33E Q26745453-E14882FD-C678-4FD9-BEAC-B6276D18D5DB Q26745580-AC686605-538A-4045-BAAB-9BAF2AB5FEDF Q26745590-87118E56-5565-417C-92BC-488189548489 Q26746099-623B119A-79CF-40AF-8DEE-BDBD436CBA8D Q26746478-A6CF6B88-D636-4306-ADF2-30A3DA0B1726 Q26747332-41476DD2-1586-4191-B313-8C7826A5B39B Q26747516-C492EBB7-2774-4733-B7B8-2F11A5FC0B81 Q26747695-C86E3157-0B86-48D3-AA21-A27C15DFACF3 Q26747703-628EEB67-B642-4215-AFEC-056E724C5120 Q26747792-300698C8-9B9B-472C-B44A-80F9E088904F Q26749054-F5A11B08-EC30-4928-B38D-794B68F129EB Q26749333-844C6569-4B30-4C7C-B709-264DF99DDDEA Q26749451-98477340-DE5A-49F5-AD3E-7DFF7945B6DA Q26749560-4DB802EA-46C8-4FB0-98FB-BB10971D1C58

P2860

The blockade of immune checkpoints in cancer immunotherapy

http://www.wikidata.org/entity/Q27860852

description

2012 nî lūn-bûn

@nan

2012 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի մարտին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

The blockade of immune checkpoints in cancer immunotherapy

@ast

The blockade of immune checkpoints in cancer immunotherapy

@en

The blockade of immune checkpoints in cancer immunotherapy

@nl

type

label

The blockade of immune checkpoints in cancer immunotherapy

@ast

The blockade of immune checkpoints in cancer immunotherapy

@en

The blockade of immune checkpoints in cancer immunotherapy

@nl

prefLabel

The blockade of immune checkpoints in cancer immunotherapy

@ast

The blockade of immune checkpoints in cancer immunotherapy

@en

The blockade of immune checkpoints in cancer immunotherapy

@nl

P1433

Q27860852-BD4E160F-BE1A-4F8F-A2FF-6E221F59210D

P1476

Q27860852-96CC2B63-82F7-4457-B091-0C88566D5262

P2093

Q27860852-EB994FBC-ECB6-439A-BAC0-B5CFE61BEA4B

P2860

Q27860852-013E34F1-6819-4E76-8441-314ED6FDC563

Q27860852-031F3485-F5F6-48F8-986D-1CD973A1A9D4

Q27860852-04CCD837-C6D7-4CFE-BBF7-22998A5F8367

Q27860852-05D3AA8F-72F4-4D57-BC30-B94024F3D553

Q27860852-063F7563-988F-42F9-A56A-6642FD36636E

Q27860852-087F9E7C-CDCE-4AD4-A30D-450BE344159F

Q27860852-0AD8392E-0FBB-42C8-92E0-AF0C5C518430

Q27860852-0B961EE7-9A35-49D1-B0F9-6E26542925A0

Q27860852-0C9CA7E0-67A4-4A4B-815E-B24564100F20

Q27860852-0FFAD6C6-DAF5-4364-924D-1E0A8922AE98

P2888

Q27860852-58C611A7-1985-4B47-B9E4-3F64861700D9

P304

Q27860852-567F1527-55FF-4F7B-AAF2-85CAC7F7222B

P31

Q27860852-C5E9A26F-F479-48AB-A4FB-99877921B73A

P3181

Q27860852-0B91DDEC-103F-4022-9427-C620D3EECFC6

P356

Q27860852-251C0559-4609-4998-A97F-A815D758221C

P407

Q27860852-41555365-B3DC-45D5-BE61-213286C3DFCB

P433

Q27860852-9390AE51-8976-4A95-8F73-63C7B49A3B02

P478

Q27860852-9FCAD634-6290-4452-9AE0-B69E2A9345C0

P577

Q27860852-4D50B18C-AEB4-4551-8300-A53A0447EB32

P5875

Q27860852-65C2D737-4C68-4FC8-AC30-40E05ACE2F55

P6179

Q27860852-1A47A212-CBED-4FAB-9837-C6085D006A51

P698

Q27860852-208E3A5A-981B-4E6C-A2CE-6DC2FC224E2B

P921

Q27860852-BB7E450C-1ECC-4A8F-9B89-900D4EE62619

P932

Q27860852-38FC7F86-FF0D-471E-B779-9E88FEAD77C1

P3181

P356

P1433

Nature Reviews Cancer

P1476

The blockade of immune checkpoints in cancer immunotherapy

@en

P2093

Drew M Pardoll

http://www.w3.org/2001/XMLSchema#string

P2860

B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion

B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells

Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production

Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death

LAG-3, a novel lymphocyte activation gene closely related to CD4

Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation

CD28/B7 system of T cell costimulation

CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms

Modulation of TCR-induced transcriptional profiles by ligation of CD28, ICOS, and CTLA-4 receptors

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.

P2888

P304

252-64

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

494347

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/NRC3239

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2012-03-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221904417

http://www.w3.org/2001/XMLSchema#string

P6179

1047946992

http://www.w3.org/2001/XMLSchema#string

P698

22437870

http://www.w3.org/2001/XMLSchema#string

P921

P932

4856023

http://www.w3.org/2001/XMLSchema#string